Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 04 June 2012 | By Ansis Helmanis,
As the result of a new patent review process, Brazilian regulatory authority Anvisa is being given the authority to deny the grant of a patent for a medical product.
The agency can make deny a decision to grant a patent if it determines the patent would impede universal access to medicines-a Brazilian constitutional right. This so-called right of "prior consent" by Anvisa would be binding on Brazil's Patent and Trademark Office (INPI).
Read more:
Patent Review Process Overview
More Breaking News from RegLink
Tags: Patent, brazil
Regulatory Focus newsletters
All the biggest regulatory news and happenings.